Skip to main content

Table 1 Summary of clinicopathologic characteristics of the patients

From: External validation suggests Integrin beta 3 as prognostic biomarker in serous ovarian adenocarcinomas

  Tumours
(from survivors/deceased patients)
Total Tumours 98 (48/50)
Tumours used in QPCR analysis 30 (15/15)
Mean age (years) 60 (57/62) (range 28-81)
FIGO Staging  
IIIa 10 (7/3)
IIIb 14 (7/7)
IIIc 73 (33/40)
IV 1 (1/0)
Surgery  
Radically operated 20 (13/7)
Residual tumour 75 (34/41)
Not available 3 (1/2)
Differentiation  
Well 15 (10/5)
Moderate 22 (10/12)
Poor 59 (26/33)
Not available 2 (2/0)
Treatment  
farmorubicine, carboplatin and cyclophosphamide 31 (16/15)
paclitaxel and carboplatin 67 (32/35)